Company Overview

Update
Founded:
2008
Headquarters:
M.P. Misgav
Funding:
$0
Categories:
Biotechnology

Neurodegenerative diseases remain unpreventable, incurable, and largely untreatable. Today, diagnosis is typically carried out through

Description

Update

Neurodegenerative diseases remain unpreventable, incurable, and largely untreatable. Today, diagnosis is typically carried out through psychiatric examination at advanced stages of the disease when the damage is significant and the potential for delaying disease progression is low.

There is an urgent need for rapid, low-cost, accurate diagnostic tests for Alzheimer’s disease (AD) and ALS (Lou Gehrig’s disease) early in their course when therapy is most effective and permits better disease management.

One in eight people over the age of 65 have AD, with over 5.1 million patients in the U.S. Incorporating an accurate diagnostic capable of monitoring disease progression will greatly ease the burden of late-stage diagnosis on families — and the health system. The U.S. Surgeon General and the UK’s NHS recognize this milestone as a top priority in the treatment of Alzheimer’s

Funding Rounds (1) - $0

Update

Investors (1)

Update
  • 7d1286e0b8e1bf3089e030b34e112d20

    SCRA

    With a one-time founding grant of $500,000 and 1,400 unused acres, the SC Legislature created SCRA..

Offices/Locations (1)

Update
  • Office

    Misgav Business Park

    M.P. Misgav, 20174

    ISR

Images (1)

Update
  • 8a4004d83fcd3e52f36d584266705ec6